Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Slightly Bullish +25

Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

📉 Guggenheim reduced its price target on Amgen to $340 from $351 while maintaining a Neutral rating following the Q1 2026 earnings release.

📊 Amgen reported non-GAAP EPS of $5.15, beating the $4.77 consensus estimate, with revenue rising 6% year-over-year to $8.62 billion.

📈 Stock performance shows a split response as Amgen beat earnings but shares slipped 7% over the past month to trade at $324.

💰 Wall Street analysts are divided on the stock, with Morgan Stanley raising its target to $326 while RBC stands at $350 and JPMorgan at $340.

🔬 Amgen's portfolio is facing a bifurcation as newer drugs like IMDELLTRA grow significantly while older franchises Prolia and Enbrel decline.

💊 Repatha, Prolia, Otezla, Tepezza, and Enbrel remain key revenue drivers alongside the obesity candidate MariTide in late-stage development.

⚠️ The growth narrative is challenged by accelerating biosimilar competition, Medicare Part D pressures, and delays for MariTide against larger incumbents like Eli Lilly.

🏛️ Amgen's regulatory outlook includes a disappointed Tepezza post-Horizon and an FDA proposal to withdraw TAVNEOS adding potential overhang.

💵 The dividend was raised 6% to $2.52 per share, providing a steady income anchor for long-term holders amidst valuation concerns.

📉 Amgen trades at a P/E ratio of 23x with a consensus analyst target of $353.43, suggesting the current price reflects most near-term upside.

🛡️ Bulls view the stock as defensive with diversified cash flows, though the bull case hinges on MariTide success and Repatha momentum.

⏳ Investors should monitor Phase 3 data for MariTide, biosimilar pacing for Prolia, and generic timing for Repatha for future catalysts.

🎯 The Guggenheim cut is viewed as a model recalibration rather than a thesis shift, signaling limited upside at current levels.

🔍 Long-term holders may see this downgrade as a prudent adjustment given the biotech giant's slowing growth profile and franchise erosion.

⚖️ Moderate position sizing is recommended for income investors who recognize Amgen needs a clear catalyst to break meaning higher from current levels.

Bullish Signals
  • Amgen beat first-quarter expectations on both revenue and earnings, delivering non-GAAP EPS of $5.15 versus the $4.77 consensus estimate.
  • Q1 revenue reached $8.62 billion, representing a 6% year-over-year increase that supports the company's growth profile despite competitive pressures.
  • Management maintained full-year guidance for revenue between $37.1 billion to $38.5 billion, signaling confidence in future performance.
  • Amgen raised its quarterly dividend by 6% to $2.52 per share, reinforcing its status as a defensive income play with a history of consistent payout increases.
  • High-growth portfolio segments demonstrated robust momentum, with IMDELLTRA growing 219%, UPLIZNA increasing 188%, and Repatha up 34%.
  • Despite analyst divergence on targets, significant peers like RBC maintain a $350 price target while Morgan Stanley raised its target to $326, indicating a bullish view exists among Wall Street institutions.
  • Amgen remains one of the largest U.S. biotechs by market capitalization near $178 billion, providing stability and scale for shareholders.
  • The forward P/E ratio of 15x suggests the stock is reasonably valued relative to future earnings, with a consensus analyst target price of $353.43 offering potential upside from recent levels.
Risk Factors
  • Guggenheim cut its price target on Amgen from $351 to $340 while maintaining a Neutral rating, signaling concerns that current valuation already reflects most of the upside potential.
  • Amgen stock has declined 7% over the past month despite beating earnings expectations, reflecting broader market caution on its growth profile.
  • Key franchises face significant erosion: Prolia sales fell 34% and Enbrel dropped 37% due to biosimilar competition and Medicare Part D pressure.
  • The obesity candidate MariTide lags behind major incumbents Eli Lilly and Novo Nordisk by years in development, creating a competitive disadvantage in the high-growth GLP-1 segment.
  • Revenue growth from core assets like Repatha (up 34%) is being offset by declining demand in others, leading to a bifurcated portfolio that may struggle to maintain total revenue momentum.
  • FDA regulatory overhang looms with proposed withdrawal approval for TAVNEOS and disappointed demand following the Horizons acquisition.
  • Tepezza demand has disappointed post-Horizon, adding uncertainty to one of the company's higher-priced specialty medicines.
  • Amgen's stock trades below the consensus analyst target of $353.43 (compared to Guggenheim's lowered $340), suggesting limited immediate upside catalysts according to cautious analysts.
Full Analysis
Guggenheim Securities has reduced its price target on Amgen (NASDAQ: AMGN) from $351 to $340, maintaining a Neutral rating following the company's Q1 2026 earnings release. While the firm updated its model rather than changing its fundamental thesis, the revision reflects Wall Street's growing caution regarding Amgen's growth trajectory as biosimilar competition intensifies and larger rivals gain ground in the obesity sector. The stock recently traded at $324, having dipped below the previous close of $329.82, and is down 7% over the past month despite delivering earnings that beat consensus estimates with non-GAAP EPS of $5.15 versus a $4.77 expectation and revenue of $8.62 billion, representing a 6% year-over-year increase. The analyst outlook highlights a significant divergence in performance across Amgen's key franchises. While newer launches showed strong momentum with IMDELLTRA growing 219%, UPLIZNA up 188%, and Repatha rising 34%, older blockbuster drugs are facing headwinds; Prolia revenue fell 34% and Enbrel declined 37% due to biosimilar competition and Medicare Part D pricing pressure. Management has maintained its full-year revenue guidance between $37.1 billion and $38.5 billion, but the split in performance underscores the challenges of protecting market share against generics and price erosion. The company's primary growth hope lies in MariTide, a late-stage glucagon-like peptide-1 (GLP-1) candidate for obesity that trails competitors like Eli Lilly and Novo Nordisk by years in development, alongside regulatory concerns regarding Tepezza demand and the FDA proposal to withdraw TAVNEOS approval. Amgen remains one of the largest biotechnology companies by market capitalization at approximately $178 billion, trading at a P/E ratio of 23x current earnings and 15x forward earnings with a consensus analyst target of $353.43. The Guggenheim downgrade falls below this consensus average, suggesting limited upside potential at current valuation levels, while competitors' firms like Morgan Stanley have raised targets to $326 or maintained them near $340-$350. The bull case for the company rests on its diversified cash flows, defensive characteristics, and a robust dividend history, with the Q1 dividend increasing 6% to $2.52 per share, which supports income-focused investors even as growth narratives await clearer catalysts from MariTide Phase 3 data or Repatha's continued momentum against generic threats.